8-K - Lexeo Therapeutics, Inc. Common Stock | StockGist

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

by reference. The information in this Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange

Regulation Fd

8.01

Other Events. On January 12, 2026, Lexeo Therapeutics, Inc. (the “Company”) issued a press release announcing positive interim Phase 1/2 clinical data of LX2020

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release issued by the Company on January 12, 2026, announcing Positive Int

Exhibits Only

Source Document

Exhibits (4)

8-K

99.1

EX-99.1

99.2

EX-99.2

99.3

EX-99.3